Keros Therapeutics
KROS
156 hedge funds and large institutions have $429M invested in Keros Therapeutics in 2025 Q1 according to their latest regulatory filings, with 48 funds opening new positions, 49 increasing their positions, 40 reducing their positions, and 50 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
23% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 40
0.13% less ownership
Funds ownership: 90.72% → 90.59% (-0.13%)
4% less first-time investments, than exits
New positions opened: 48 | Existing positions closed: 50
3% less funds holding
Funds holding: 161 → 156 (-5)
26% less capital invested
Capital invested by funds: $582M → $429M (-$153M)
27% less call options, than puts
Call options by funds: $12.5M | Put options by funds: $17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$44.9M |
| 2 |
JP Morgan Chase
New York
|
+$27.7M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$23.2M |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$17M |
| 5 |
D.E. Shaw & Co
New York
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$59.2M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$30M |
| 3 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$26.7M |
| 4 |
Holocene Advisors
New York
|
-$19M |
| 5 |
JFG
Jefferies Financial Group
New York
|
-$13.7M |
KROS Hedge Fund Activity: Q1 2025 in Review
156 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q1 2025, worth a combined $429M — down 26% from $582M a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of KROS and 48 opened new positions — a net loss of 2 holders — while 40 trimmed existing stakes and 49 added.
The largest buyer was Nuveen, adding an estimated $44.9M. The largest seller was Fidelity Investments, cutting an estimated $59.2M.
- 156 institutional investors held Keros Therapeutics (KROS) as of Q1 2025, down from 161 in Q4 2024.
- Funds reported $429M of Keros Therapeutics stock for Q1 2025, down 26% quarter-over-quarter.
- 48 funds opened new Keros Therapeutics positions in Q1 2025 and 50 closed out, a net change of -2 holders.
- The largest Keros Therapeutics buyer in Q1 2025 was Nuveen, an estimated $44.9M added.
- The largest Keros Therapeutics seller in Q1 2025 was Fidelity Investments, an estimated $59.2M sold.
Based on aggregated 13F filings for Q1 2025.